INTRODUCTION
Breast cancer is the second most common cancer worldwide and the most common cancer in women in developed countries. Worldwide, the estimated incidence of 1.4 million cases and 458 000 deaths per year 1 correspond to 23% of total new cancer cases and 14% of total cancer deaths, respectively. 2 In recent years, the breast cancer incidence rates have been increasing throughout the world. 3 Age-adjusted incidence rates over three decades show an increase of 30-40% from the 1970s to the 1990s in most countries, notably most affecting women aged > 50 years. 4 In contrast, mortality rates have decreased with an annual decline of 2.3% in age-adjusted breast cancer-Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com related mortality from 1990-2002 in the USA. 5 In Europe, similar trends were observed in breast cancer mortality rates, with reductions of 15% between 1980 and 2000, 6 and 6.9% between 2002 and 2007. 7 However, improvements in survival have not been homogeneous, as suggested by epidemiologic studies among women with breast cancer. Race/ethnic disparities persist in cancer incidence and survival. [8] [9] [10] [11] In addition, women with lower socioeconomic status have a higher risk of being diagnosed with advanced disease, and of receiving inadequate treatment, with consequent lower survival rates.
12 In addition to demographic and socioeconomic factors, it is well established that tumor biological characteristics influence prognosis and survival. Patients with histological Grade 3 tumors have poorer overall survival when compared with patients with Grade 1 or 2 tumors.
13 Furthermore, women with estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive tumors have a better prognosis than those with hormone receptor-negative tumors.
14 In Portugal, breast cancer ranks first among cancers affecting women, 15 with an agestandardized incidence rate of 60.0/100 000 females.
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Breast cancer mortality rates have also declined in the Portuguese population in the last decade with an estimated annual percent change of -2% per year, with the largest declines observed in the regions that had higher mortality rates at the beginning of the period 16 . Overall, mortality rates seem to differ between Portuguese geographical regions, with a mortality rate of 9.5/1 000 inhabitants in Lisboa e Vale do Tejo, 14.4/1 000 in Alentejo, 11.6/1 000 in Algarve and 11.0/1 000 in Região Autónoma da Madeira. 17 Hence, the scope of the present work relies on acquiring a deeper understanding of survival patterns for breast cancer patients in the Portuguese population. Specifically, we report the breast cancer profile -survival differences and associated factors -among women living in the southern region of Portugal. The major goal of the authors is to provide updated information to support national actions towards the reduction or elimination of disparities among Portuguese women with breast cancer.
MATERIAL AND METHODS

Study Design
We have conducted a population-based retrospective study of female breast cancer cases from the Southern Portugal Cancer Registry (ROR-Sul). ROR-Sul is a population-based cancer registry established in 1988, which includes the south region of Portugal. This region covers a territory of 39 500 km 2 and encompasses a population of almost 4.5 million inhabitants. 18 
Selection of patients
Patients included in this study had confirmed female primary breast cancer diagnosed between January 1, 2005 and December 31, 2005, and were residents in the south region of Portugal at the time of diagnosis.
Pathologic Diagnostic Criteria
Topography (primary site), histological classification and behavior were based on the ICD-O, 3 rd revision. 19 Staging of breast cancer was classified according to the American Joint Committee on Cancer Criteria (AJCC), 6 th Edition. 20 Data was extracted from ROR-Sul database and supplemented with medical information from the clinical charts as needed. Collected variables included demographic characteristics (birth date, age at diagnosis, place of residence), clinical characterization (date of first medical consultation, date of diagnosis, topography, histology, tumor histological grade, ER and PR status, human epidermal growth factor receptor 2 (HER2) expression, stage), treatment options (surgery, chemotherapy, radiotherapy and hormone therapy), disease status (if death, date of death; if relapse, date of relapse). Cut-off date was December 31, 2010.
Data analysis
Frequencies were calculated for variables related to demographic, clinical and pathologic characteristics to determine their overall distribution, among stages and among geographical regions. Quantitative variables were calculated by the mean or median depending on data distribution. The differences in variable distribution between geographical regions were examined using Chisquare (qualitative variables) test and ANOVA (quantitative variables) to obtain p-values. Data was analyzed using Microsoft Excel 2007 and Stata/SE 12.0 for Windows, USA. Statistical significance was assessed by two-tailed tests with an alpha level of 0.05. Survival was calculated by the Kaplan-Meyer method and compared using Log-Rank test.
RESULTS
A total of 2 821 breast cancer cases diagnosed throughout 2005 were registered in ROR-Sul database. Of these, 2 725 cases were effectively resident in the Southern Portugal territory at the time of diagnosis (2 150 from Lisboa e Vale do Tejo (LVT), 277 from Alentejo, 193 from Algarve and 105 from Região Autónoma da Madeira (RAM)). Because the vast majority of cases were in the LVT region (79%), only 55% of these were randomly selected to be included in the study. After randomization we have confirmed that the remaining 45% of the population had the same characteristics as the included ones. All 575 cases from other regions were included. Total number of cases reviewed for the present study was 1 753 (corresponding to 2 104 clinical charts from different Portuguese health institutions). Following appropriate revision, 399 cases were excluded from the final analysis due to inconsistencies on inclusion criteria (e.g. date of diagnosis was different from 2005, histopathological reports did not corroborate breast invasive disease). Hence, final analysis included 1 354 cases.
Patient's characteristics
A total of 1 354 patients were included from 27 Portuguese health institutions. Patient characteristics are presented in Table 1 . Evaluated cases were distributed as follows: 905 patients from LVT, 186 patients from Alentejo, 166 from Algarve and 97 patients from RAM. The mean age at diagnosis was 61 years (with a standard deviation of 14 years, a minimum of 22 and a maximum of 97 years) and 50% of patients were diagnosed between 40 and 65 years of age. We observed geographical variations in age distribution with an aging population in Alentejo (> 50% of patients older than 65-years old). The most frequent (4) 10 (1) 13 (1) 1 (0) 73 (8) 142 (76) 6 (3) 4 (2) 4 (2) 3 (2) 27 (15) 129 (78) 14 (8) 2 (1) 2 (1) 0 (0) 19 (12) 80 (82) 5 (6) 2 (2) 1 (1) presented as ER-negative/PR-negative/HER2-positive and 9% were triple negative (ER-negative/PR-negative/HER2-negative). We observed some significant differences in the geographical distribution of tumor profiles, with a higher incidence of triple-negative tumors in RAM and a higher incidence of triple-positive tumors in the Algarve compared with other regions.
Treatment patterns
Eighty-eight percent of patients (1195 cases) were submitted to a surgical procedure, with conservative surgery being performed in 46% and radical mastectomy in 42% of cases. Chemotherapy was administered to 53% of patients, radiotherapy was performed in 61% and hormone therapy was given to 64% of patients. Looking at treatment options by tumor stage, there was an association between stage and surgery, with less surgery being performed in Stage III (18%) and IV (2%), and an association between chemotherapy and tumor stage, with more chemotherapy being given to Stage II patients (49%). Patterns of treatment were not different between geographical regions. Regarding the time elapsed between diagnosis and treatment we registered a similar interval of 2.3 months in all geographical regions.
Survival
We observed a 5-year overall survival of 80% for the population in the present study (Fig. 1) . There is an association between survival and staging (p = 0.00), with a 5-year survival of 92% for patients presenting with Stage I disease, 86% for Stage II, 60% for Stage III and a survival of 20% for Stage IV (Fig. 2) . Kaplan-Meier plots for overall survival by hormone receptor expression revealed an improved survival in the ER-positive group compared with the ER-negative group, and in the PR-positive group compared with the PR-negative group. When analyzing survival accordingly with tumor HR/HER2-triple phenotypes (p = 0.00), we found a progressive decreasing survival from the triple positive (ER-positive/PR-positive/HER2-positive) tumor sub-type to the ER-positive/PR-positive/HER2-negative, ER-negative/PR-negative/HER2-positive and ERnegative/PR-negative/HER2-negative (Fig. 3 ). There were no survival differences for the studied geographical regions (p = 0.7637) (Fig. 4) .
DISCUSSION
This study reports a unique analysis of possible geographical variations in breast cancer epidemiology and management across South Portugal. Hence, the disclosure of this information will support further understanding of the magnitude of unmet medical needs, in parallel with the knowledge of high risk regions for breast cancer in the southern territory of Portugal.
In this retrospective study, survival was substantially inferior in patients with advanced disease, as well as in patients with triple-negative tumors. Geographical region of residence did not substantially affect survival. The observed differences in age distribution by geographical regions, with an aged population in Alentejo, are in accordance with our previous knowledge of the Portuguese population distribution between regions, with more elderly people in rural areas. In our study, the incidence of early stage disease was lower in RAM. The difference between regions may be due to differences in access to health care. Also it has been suggested by some studies 11, 12 that women who have higher education are more likely to present with early-stage breast cancer, and this can also be responsible for these differences with less educated women in the more rural areas. ER-positive breast cancers are known to correlate with a better outcome than those that are ER-negative, as they respond better to hormone therapy. In our study, we did not find differences in the incidence of HR tumor expression patterns among regions. On the contrary, we noticed differences when considering HER2 status, with a high incidence of HER2-negative tumors in RAM, and a high number of HER2-positive tumors in the Algarve. Further studies will need to be completed to clarify whether these differences represent a truly geographical variation of biologically distinct diseases, or solely reflect differences in the assay methods used to evaluate HER2 status. Survival analysis by stage confirmed a higher survival at 5 years in patients with localized disease and lower survival in patients with advanced disease. In addition, we confirmed an influence of tumor biological characteristics for survival, showing a better outcome for the triple-positive HR-positive/ HER2-positive patients group and worse outcome for the triple-negative group. Finally, there were no evident differences in survival between Portuguese geographical regions in our study.
Our results need to be considered in light of the study strengths and weaknesses. The main strength of this study is the number of patients included. Nevertheless, the distribution by geographical region is not equitable, and number of patients is relatively small in some of the sub-groups (e.g. RAM). We also recognize other significant limitations. The study was retrospective in nature, and data quality was dependent on the thoroughness of data collection and medical records. Also, we acknowledge the possible effect of measurable and no-measurable confounders in our results.
In conclusion, our study confirms the association between patient survival and tumor stage, hormone receptor and HER2 status, and raises important questions, namely regarding the geographical variation of tumor subtypes and the apparent inexistence of survival differences in breast cancer patients across the various geographical studied regions. 
